The Japanese journal of neuropsychology

Full Text of this Article
in Japanese PDF (743K)

ArticleTitle	Development of Muse cell therapy for ischemic stroke
Language	J
AuthorList	Kuniyasu Niizuma^1)～3), Teiji Tominaga³⁾
Affiliation	¹⁾Department of Neurosurgical Engineering and Translational Neuroscience, Graduate School of Biomedical Engineering, Tohoku University ²⁾Department of Neurosurgical Engineering and Translational Neuroscience, Tohoku University Graduate School of Medicine ³⁾Department of Neurosurgery, Tohoku University Graduate School of Medicine
Publication	Japanese Journal of Neuropsychology: 37 (1), 21-28, 2021
Received
Accepted
Abstract	Cerebral infarction accounts for～60% of the total stroke, and causes 73,000 deaths every year, total number of patients is 1.8 million, and annual medical expenses exceeds 1 trillion yen in Japan. The number of patients is increasing and cerebral infarction became a serious problem from the viewpoint of the national medical economy. Even with the current sophisticated treatments including thrombolysis and thrombectomy, more than half patients get disabled. Therefore, it is imperative to develop a new treatment to enhance recovery and restore the lost neurological functions. Multilineage-differentiating stress-enduring (Muse) cells are endogenous stem cells with pluripotency, collectable as pluripotent surface marker, SSEA-3, from various kinds of sources such as the bone marrow, adipose tissue and dermis, as well as from commercially released cultured fibroblasts. After transplantation, Muse cells recognize the injured site through their specific receptor for damage signal, home preferentially into the tissue by intravenous injection and spontaneously differentiate into tissue-compatible cells to replace the lost cells, and repair the tissue, delivering functional and structural regeneration. Based on these unique properties, the simple strategy; collect Muse cells by SSEA-3, expand them and treat patients by systemic administration is available. In this report, we describe current status of stem cell therapy in ischemic stroke, and the development of new therapies using Muse cells.
Keywords	regenerative medicine, Muse cell, stem cells, cerebral infarction